Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
MARX Biotech CoROCO:7731 -3.18%10 EV-to-FCF is -17.29 as of Jul. 18, 2026. GuruFocus rates ROCO:7731 with a GF Score™ of 10/100. The stock has 4 warning signs investors should review. Among 406 Healthcare Providers & Services companies, MARX Biotech Co ranks worse than 246305.17% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, MARX Biotech Co's Enterprise Value is NT$2,815.0 Mil.
MARX Biotech Co's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was NT$-162.8 Mil. Therefore, MARX Biotech Co's EV-to-FCF for today is -17.29.
The historical rank and industry rank for MARX Biotech Co's EV-to-FCF or its related term are showing as below:
ROCO:7731'
s EV-to-FCF Range Over the Past 10 Years
Min: -227.68 Med: -19.85 Max: -6.73
Current: -18.34
During the past 6 years, the highest EV-to-FCF of MARX Biotech Co was -6.73. The lowest was -227.68. And the median was -19.85.
ROCO:7731's EV-to-FCF is ranked worse than 100% of 406
companies
in the Healthcare Providers & Services industry
Industry Median: 17.99
vs ROCO:7731: -18.34
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
MARX Biotech Co's PE Ratio (TTM) for today is calculated as:
MARX Biotech Co's share price for today is NT$4.87.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. MARX Biotech Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was NT$0.080.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
MARX Biotech Co EV-to-FCF Related Terms
MARX Biotech Co EV-to-FCF Historical Data
* Premium members only.
The historical data trend for MARX Biotech Co's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Pharmaceutical Retailers subindustry, MARX Biotech Co's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MARX Biotech Co EV-to-FCF vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, MARX Biotech Co's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where MARX Biotech Co's EV-to-FCF falls into.
MARX Biotech Co's current Enterprise Value is NT$2,815.0 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. MARX Biotech Co's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was NT$-162.8 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MARX Biotech Co (ROCO:7731) has a EV-to-FCF of -17.29 as of Jul. 18, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on MARX Biotech Co and its competitors. According to the industry distribution chart, MARX Biotech Co ranks #999999 out of 406 companies in the Healthcare Providers & Services industry.
Is MARX Biotech Co's EV-to-FCF too high?
MARX Biotech Co's current EV-to-FCF is -17.29. Based on the distribution chart, MARX Biotech Co ranks #999999 out of 406 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, MARX Biotech Co has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does MARX Biotech Co's EV-to-FCF compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, MARX Biotech Co ranks #999999 out of 406 companies for EV-to-FCF. This places MARX Biotech Co in the lower half of its industry. The industry median EV-to-FCF is 17.99. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Healthcare Providers & Services company?
The median EV-to-FCF among Healthcare Providers & Services companies is 17.99, based on 406 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on MARX Biotech Co and its competitors. For the Healthcare Providers & Services industry, the median EV-to-FCF is 17.99 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MARX Biotech Co's current EV-to-FCF is -17.29. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MARX Biotech Co stock overvalued right now?
MARX Biotech Co (ROCO:7731) has a current EV-to-FCF of -17.29. The current EV-to-FCF is -17.29. MARX Biotech Co's overall GF Score™ is 10/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For MARX Biotech Co (ROCO:7731), the current EV-to-FCF is -17.29 as of Jul. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
MARX Biotech Co Ltd is a retail company which has developed an O2O and OMO full-channel layout in the online Internet platform and cosmeceutical retail market, and has successfully established itself in the market and Build trust and operational growth on the channel side. It has has established more than three thousand large and small cosmeceutical pharmacies in Taiwan, including: Dashu Pharmacy, Dingding Pharmacy, Cosmed, Watsons, Spring Pharmacy, New Gaoqiao Pharmacy, Anlier Pharmacies, etc.
10GF Score
Get the complete analysis for ROCO:7731
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:7731 has been successfully added to your 
